AU2002346812A1 - Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors - Google Patents

Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors

Info

Publication number: AU2002346812A1
Authority: AU; Australia
Prior art keywords: oxazolidine; protease; inhibitors; phenyl; compounds
Prior art date: 2001-12-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002346812A

Inventor

Hans-Peter Buchstaller

Oliver Poschke

Andreas Willems

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Patent GmbH

Original Assignee

Merck Patent GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-04

Filing date

2002-10-31

Publication date

2003-06-17

2002-10-31 Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH

2003-06-17 Publication of AU2002346812A1 publication Critical patent/AU2002346812A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU2002346812A 2001-12-04 2002-10-31 Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors Abandoned AU2002346812A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10159453.4		2001-12-04
DE10159453A DE10159453A1 (en)	2001-12-04	2001-12-04	Use of 1-phenyl-oxazolidin-2-one compounds as a protease
PCT/EP2002/012162 WO2003047572A1 (en)	2001-12-04	2002-10-31	Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors

Publications (1)

Publication Number	Publication Date
AU2002346812A1 true AU2002346812A1 (en)	2003-06-17

Family

ID=7707942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2002346812A Abandoned AU2002346812A1 (en)	2001-12-04	2002-10-31	Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors

Country Status (4)

Country	Link
AR (1)	AR037631A1 (en)
AU (1)	AU2002346812A1 (en)
DE (1)	DE10159453A1 (en)
WO (1)	WO2003047572A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002950217A0 (en) *	2002-07-16	2002-09-12	Prana Biotechnology Limited	8- Hydroxy Quinoline Derivatives
EP1718975A2 (en) *	2004-02-18	2006-11-08	Bayer HealthCare AG	Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)
JP5752691B2 (en)	2009-09-29	2015-07-22	グラクソグループリミテッドＧｌａｘｏＧｒｏｕｐＬｉｍｉｔｅｄ	New compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4332384A1 (en) *	1993-09-23	1995-03-30	Merck Patent Gmbh	Adhesion receptor antagonists III
EP0710657B1 (en) *	1994-11-02	1998-08-26	MERCK PATENT GmbH	Antagonists of adhesion receptors
DE19516483A1 (en) *	1995-05-05	1996-11-07	Merck Patent Gmbh	Adhesion receptor antagonists
PL330240A1 (en) *	1996-05-31	1999-05-10	Scripps Research Inst	Methods and compositions useful in inhibiting angiogenesis in which alphavbeta5 acts as intermediary
DE19755268A1 (en) *	1997-12-12	1999-06-17	Merck Patent Gmbh	Benzamidine derivatives

2001
- 2001-12-04 DE DE10159453A patent/DE10159453A1/en not_active Withdrawn
2002
- 2002-10-31 WO PCT/EP2002/012162 patent/WO2003047572A1/en not_active Ceased
- 2002-10-31 AU AU2002346812A patent/AU2002346812A1/en not_active Abandoned
- 2002-12-04 AR ARP020104681A patent/AR037631A1/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
AR037631A1 (en)	2004-11-17
DE10159453A1 (en)	2003-06-18
WO2003047572A1 (en)	2003-06-12

Publication	Publication Date	Title
AU2002256418A1 (en)	2002-11-11	Inhibitors of bace
AU2002357882A1 (en)	2003-06-30	Small-molecule inhibitors of interleukin-2
AU2002340031A1 (en)	2003-04-14	Compounds useful as reversible inhibitors of cysteine proteases
AU2001245764A1 (en)	2001-09-24	Novel compounds and compositions as protease inhibitors
AU2002238103A1 (en)	2002-08-28	Use of beta-lactamase inhibitors as neuroprotectants
AU2002338734A1 (en)	2003-07-03	Use of phosphorodiesterase IV inhibitors
AU2002306734A1 (en)	2002-10-03	Inhibitors of plasmepsins
HUP0401641A3 (en)	2007-02-28	Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
AU2003215635A1 (en)	2003-10-13	Thiazol-2-yl-imine compounds as pde-7 inhibitors
AU2003269984A1 (en)	2004-03-11	Protease inhibitors
AU2003295638A1 (en)	2004-06-18	NOVEL INHIBITORS OF Beta-LACTAMASE
AU2002342682A1 (en)	2002-11-25	Protease inhibitors
AU2002346812A1 (en)	2003-06-17	Use of 1-phenyl-oxazolidine-2-one compounds as protease m inhibitors
AU2002348465A1 (en)	2003-05-06	Alpha-hydroxyarylbutanamine inhibitors of aspartyl protease
AU2002305868A1 (en)	2002-12-23	Inhibitors of reggamma
AU2003245614A1 (en)	2004-01-06	Ureido-substituted aniline compounds useful as serine protease inhibitors
EP1238585B8 (en)	2005-07-06	Use of esterquats
AU2003263738A1 (en)	2003-12-02	Protease inhibitors
AU2002221882A1 (en)	2002-06-03	Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2002258749A1 (en)	2002-10-08	Inhibitors of glycosaminoglycans
AU2003238034A1 (en)	2004-01-23	Novel use of imidazotriazinones
AU2003304496A1 (en)	2005-04-27	Protease inhibitors
AU2003233642A1 (en)	2003-12-12	Protease inhibitors
AU2002328906A1 (en)	2003-03-03	Inhibitors of polyq-aggregation
AU2002323648A1 (en)	2003-04-01	Sulfonamide compounds as protease inhibitors

Legal Events

Date	Code	Title	Description
2004-08-19	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase